Summit Therapeutics Inc (SMMT)

[roadkilll]

Drop based on OS, not sure why anyone thought Ivonescimab would show significant OS data.

Ivonescimab got approval in China based on progression free survival
HARMONi-2

Ivonescimab, reduced the risk of tumor progression by 49% compared to Keytruda
At the median, patients treated with ivonescimab went 11.1 months before their tumors began to grow again compared to 5.8 months for patients on Keytruda. 

HARMONi,
The actual numbers were not released for the latest trial. Complete data to be released at future medical conference. Summit wants hope the OS data matures and is significant.

Summit does plan to submit BLA filing based on the data already collected.

- Personally not expecting OS to be significant in my investment thesis. If PFS is consistent with previous trials patients should be given the ivonescimab option. A slower path to approval unless doctors and patients pressure FDA